AgomAb Therapeutics
Franklin Rooseveltlaan 348 126
9000 Gent
BE
AgomAb Therapeutics
Foundation date
2017
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
- #Diseases of the blood and blood-forming organs - immune disorders
- #Endocrine - nutritional and metabolic diseases
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Our unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
Upcoming events
All events-
2211 '21
Translational Immunology
Event by: VIB -
2909 '21
BIOSPAIN 2021
Event by: ASEBIO, the Spanish Bioindustry Association -
2710 '21
New Horizons in Alzheimer's Disease
Event by: VIB
Latest news
More news-
Mithra announces topline results for COVID-19 Phase II Study
1 day ago
Read more
-
Biocartis announces restart of its high-throughput cartridge manufacturing line
Thursday September 23rd 2021
Read more
-
Rewind Therapeutics appoints Anja Harmeier, PhD, MBA, as Chief Executive Officer
Wednesday September 22nd 2021
Read more